Latest Artificial Intelligence News

Tivan Limited has restarted fieldwork at its Sandover AI Project in central Australia, leveraging AI-driven targeting alongside enhanced collaboration with EARTH AI. Results from new electromagnetic surveys are expected by March 2026, setting the stage for expanded drilling campaigns.

Argenica Therapeutics’ AI-powered reanalysis of its Phase 2 trial reveals significant efficacy of ARG-007 in severe acute ischemic stroke patients, highlighting improved functional outcomes and reduced brain damage.

SenSen Networks reports robust Q2 FY26 revenue momentum, driven by five new city wins in North America, a surge in variable licence fees in Australia, and expanded fuel retail site deployments.

Nanoveu’s subsidiary EMASS has teamed up with Semtech to integrate ultra-low-power AI with long-range LoRa connectivity, promising smarter, battery-efficient IoT devices for industrial and smart city applications.

DigiCo Infrastructure REIT appoints Michael Juniper as CEO, signaling a strategic push into advanced data centre development amid rising cloud and AI demand. Chris Maher shifts focus to government relations, underscoring regulatory challenges ahead.

Algorae Pharmaceuticals has independently validated its AI-driven drug combination platform, AlgoraeOS v1, confirming its ability to predict synergistic cancer drug pairs. The company has also launched an upgraded version, AlgoraeOS v2, poised to enhance drug discovery efforts.

NEXTDC has inked a Memorandum of Understanding with OpenAI to develop a cutting-edge sovereign AI infrastructure in Sydney, marking a major step in Australia’s digital sovereignty ambitions.

Pathkey.AI Ltd has announced a pro rata non-renounceable rights issue to raise approximately $920,517, alongside a $2.5 million placement, aiming to fund enhancements to its AI platform and strategic expansion.

BrainChip Holdings has closed its Share Purchase Plan with subscriptions exceeding the $2 million target by nearly $1 million, complementing a recent $35 million placement. The Board’s decision to accept all applications reflects robust shareholder confidence.

Verbrec Limited has completed a transformative acquisition of Alliance Automation, significantly expanding its digital capabilities and service footprint across Australia and New Zealand.

Oneview Healthcare reported robust commercial growth in 2025, driven by new US client wins and the launch of its AI-powered care assistant, Ovie. The company enters 2026 with a confident outlook focused on expanding its US footprint and advancing digital health innovation.

Imagion Biosystems is set to submit its Investigational New Drug application for the MagSense® HER2 breast cancer imaging agent in December 2025, paving the way for a Phase 2 clinical trial in early 2026. Collaboration with Wayne State University has refined the trial design, promising improved patient safety and diagnostic precision.